Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Short-term Investments (2017 - 2025)

Corcept Therapeutics (CORT) has disclosed Short-term Investments for 9 consecutive years, with $251.7 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 1.57% to $251.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $251.7 million through Dec 2025, down 1.57% year-over-year, with the annual reading at $251.7 million for FY2025, 1.57% down from the prior year.
  • Short-term Investments hit $251.7 million in Q4 2025 for Corcept Therapeutics, down from $296.5 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $365.3 million in Q4 2022 to a low of $145.9 million in Q4 2021.
  • Historically, Short-term Investments has averaged $264.7 million across 5 years, with a median of $258.3 million in 2024.
  • Biggest five-year swings in Short-term Investments: tumbled 59.97% in 2021 and later surged 150.38% in 2022.
  • Year by year, Short-term Investments stood at $145.9 million in 2021, then skyrocketed by 150.38% to $365.3 million in 2022, then tumbled by 36.31% to $232.7 million in 2023, then rose by 9.88% to $255.7 million in 2024, then dropped by 1.57% to $251.7 million in 2025.
  • Business Quant data shows Short-term Investments for CORT at $251.7 million in Q4 2025, $296.5 million in Q3 2025, and $239.5 million in Q2 2025.